Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
AFTBVAC
TUBERCULOSIS
Framework programme: 5
Project number:
QLK2-CT-2002-01613
EC contribution: € 2 000 000
Duration: 36 months
Type: RS, DM
Starting date: 1 December 2002
Graphic element Development of a Tuberculosis Vaccine in Africa
Keywords: Tuberculosis; vaccine; infection; safety; immunogenicity. cohort

Summary:

The objective of the project is to define the safety and immunogenicity of two new, virally-vectored vaccines to prevent tuberculosis (TB) in adult Africans, and to study cohorts of individuals at high risk of tuberculosis to evaluate the incidence of tuberculosis infection and disease, with the view to selecting appropriate populations and sites for future testing of TB vaccines in Africa.  

The specific objectives of the project are:

  1. to manufacture batches of the two subunit vaccines, MVA-Ag85A and FP9-Ag85A in a GMP facility to a standard required by European regulatory authorities
  2. to evaluate the safety and immunogenicity of these subunit vaccines in African volunteers without evidence of mycobacterial infection
  3. to conduct phase 1 studies of these vaccines in individuals already exposed to mycobacterial infection
  4. to test these two subunit vaccines in a heterologous prime-boost immunisation regime
  5. to measure incidence rates of TB infection and disease in cohorts of household contacts of TB cases and HIV infected individuals.

Brief description:

This three-year project will be conducted jointly in The Gambia and Senegal, using a standardised methodology. It is divided into two main parts, whose objectives are complementary and whose activities will be intertwined at the level of immunology: a phase 1 clinical trial of recombinant vaccines against TB (Work Packages 1 to 4) and the establishment of pre-vaccine cohorts (Work Packages 5 and 6). In Work Packages 1 to 3, safety and immunogenicity of the MVA and FP9 TB vaccines will be assessed in small groups of non-TB infected and in TB-infected volunteers in The Gambia. In Work Package 4, the safety and immunogenicity of these vaccines will be evaluated in prime-boost combination regimes in non-infected and infected African volunteers. In Work Packages 5 and 6, high-risk cohorts, including household contacts of TB cases and HIV-infected individuals, will be established in The Gambia and in Senegal in order to measure the incidence of TB infection and TB disease in these high-risk populations with the view to identifying suitable populations for future vaccine trials.

Coordinator:

Christian Lienhardt
Institut de Recherche pour le Développement (IRD)
Route des Pères maristes
B.P. 1386
Dakar
Sénégal
Tel: +221 849 3562
Fax: +221 832 4307
E-mail: lienhardt@dakar.ird.sn

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Adrian HillNuffield Department of Medicine
John Radcliffe Hospital
UK-OX3 9DU Oxford
United Kingdom
Tel: +44 1865 222301
Fax: +44 1865 221921
E-mail: Adrian.hill@imm.ox.ac.uk
3Roger BrookesMRC Laboratories
PO Box 273
Atlantic Boulevard
Fajara
Gambia
Tel: +220 495 442
Fax: +220 496 513
E-mail: rbrookes@mrc.gm
4Kris HuygenInstitut Pasteur de Bruxelles
642 Englandstraat
BE-1180 Brussels
Belgium
Tel: +32 2 373 3370
Fax : +32 2 373 3367
E-mail: khuygen@pasteur.be

 
 
top
Graphic element